NK-1 receptor antagonists: A new generation of anticancer drugs

Mini-Reviews in Medicinal Chemistry

Volumn 12, Issue 7, 2012, Pages 593-599

  Munoz M ^a   Covenas R ^b  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Apoptosis; Metastasis; Neoangiogenesis; Substance P; Tumor cells

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; ANXIOLYTIC AGENT; APREPITANT; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOSTATIC AGENT; INDOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MORPHOLINE; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; PACLITAXEL; PIPERIDINE DERIVATIVE; VINBLASTINE;

ANALGESIC ACTIVITY; ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANXIETY; APOPTOSIS; ARTICLE; BRAIN DISEASE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CANCER RISK; CELL DEATH; CELL MIGRATION; CELL PROLIFERATION; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CYTOPLASM; CYTOTOXICITY; DNA SYNTHESIS; DRUG EFFECT; DRUG SAFETY; EPIDERMIS; FOLLOW UP; GENE ACTIVATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INTERNALIZATION; KIDNEY DISEASE; LIVER PROTECTION; LIVER TOXICITY; MELANOMA; METASTASIS; MITOGENESIS; NEPHROTOXICITY; NEUROGENIC INFLAMMATION; NEUROPROTECTION; POLYNEUROPATHY; PREMEDICATION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RENAL PROTECTION; SEIZURE; SIGNAL TRANSDUCTION; STOMACH CANCER; TREATMENT INDICATION; TUMOR CELL; TUMOR DIFFERENTIATION; VISCERAL PAIN; VOMITING;

EID: 84861726798     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/138955712800626692     Document Type: Article

References (94)

1. Muñoz, M.; Rosso, M.; Pérez, A.; Coveñas, R.; Rosso, R.; Zamarriego, C.; Soult, J.A.; Montero, I. Antitumoural action of the neurokinin-1-receptor antagonist L-733,060 and mitogenic action of substance P on human retinoblastoma cell lines. Invest. Ophthalmol. Vis. Sci., 2005, 46, 2567-70.
2. Muñoz, M.; Rosso, M.; Coveñas, R.; Montero, I.; González-Moles, M.A.; Robles, M.J. Neurokinin-1 receptors located in human retinoblastoma cell lines: antitumor action of its antagonist, L-732,138. Invest. Ophthalmol. Vis. Sci., 2007, 48, 2775-81.
3. Muñoz, M.; Coveñas, R. Neurokinin-1 receptor: a new promising target in the treatment of cancer. Discov. Med., 2010, 10, 305-13.
4. Muñoz, M.; Pérez, A.; Coveñas, R.; Rosso, M.; Castro, E. Antitumoural action of L-733,060 on neuroblastoma and glioma cell lines. Arch. Ital. Biol., 2004, 142, 105-12.
5. Muñoz, M.; Pérez, A.; Rosso, M.; Zamarriego, C.; Rosso, R. Antitumoural action of NK1 receptor antagonist L-733,060 on human melanoma cell lines. Melanoma Res., 2004, 14, 183-8.
6. Muñoz, M.; Rosso, M.; Pérez, A.; Coveñas, R.; Rosso, R.; Zamarriego, C.; Piruat, J.I. The NK1 receptor is involved in the antitumoural action of L-733,060 and in the mitogenic action of substance P on neuroblastoma and glioma cell lines. Neuropeptides, 2005, 39, 427-32.
7. Muñoz, M.; Rosso, M.; Coveñas, R. A new frontier in the treatment of cancer: NK-1 receptor antagonists. Curr. Med. Chem., 2010, 17, 504-16.
8. Muñoz, M.; Rosso, M.; Casinello, F.; Coveñas, R. Paravertebral anesthesia: how substance P and the NK-1 receptor could be involved in regional block and breast cancer recurrence. Breast Cancer Res. Treat., 2010, 122, 601-3.
9. Muñoz, M.; Rosso, M.; Robles-Frías, M.J.; Salinas-Martín, M.V.; Rosso, R.; Gonzalez-Ortega, A.; Coveñas, R. The NK-1 receptor is expressed in human melanoma and is involved in the antitumor action of the NK-1 receptor antagonist aprepitant on melanoma cell lines. Lab. Invest., 2010, 90, 1259-69.
10. González-Moles, M.A.; Mosqueda-Taylor, A.; Esteban, F.; Gil-Montoya, J.A.; Díaz-Franco, M.A.; Delgado, M.; Muñoz, M. Cell proliferation associated with actions of the substance P/NK-1 receptor complex in keratocystic odontogenic tumours. Oral. Oncol., 2008, 44, 1127-33.
11. Brener, S.; González-Moles, M. A,; Tostes, D.; Esteban, F.; Gil-Montoya, J.A.; Ruiz-Avila, I.; Bravo, M.; Muñoz, M. A role for the substance P/NK-1 receptor complex in cell proliferation in oral squamous cell carcinoma. Anticancer. Res., 2009, 29, 2323-9.
12. Esteban, F.; González-Moles, M.A.; Castro, D.; Martín-Jaén, M.M.; Redondo, M.; Ruiz-Avila, I.; Rosso, M.; Muñoz, M. Expression of substance P and neurokinin-1-receptor in laryngeal cancer: linking chronic inflammation to cancer promotion and progression. Histopathology, 2009, 54, 258-60.
13. Friess, H.; Zhu, Z.; Liard, V.; Shi, X.; Shrikhande, S.V.; Wang, L.; Lieb, K.; Korc, M.; Palma, C.; Zimmermann, A.; Reubi, J.C.; Buchler, M.W. Neurokinin-1 receptor expression and its potential effects on tumor growth in human pancreatic cancer. Lab. Invest., 2003, 83, 731-42.
14. Palma, C., Nardelli, F.; Manzini, S.; Maggi, C.A. Substance P activates responses correlated with tumour growth in human glioma cells line bearing tachykinin NK1 receptors. Br. J. Cancer, 1999, 79, 236-43.
15. Muñoz, M.; Rosso, M.; Coveñas, R. The NK-1 receptor is involved in the antitumoural action of L-733,060 and in the mitogenic action of substance P on human pancreatic cancer cell lines. Lett. Drug Des. Discovery, 2006, 3, 323-9.
16. Muñoz, M.; Rosso, M.; Aguilar, F.J.; González-Moles, M.A.; Redondo, M.; Esteban, F. NK-1 receptor antagonists induce apoptosis and counteract substance P-related mitogenesis in human laryngeal cancer cell line HEp-2. Investig. New Drugs, 2008, 26, 111-8.
17. Rosso, M.; Robles-Frías, M.J.; Coveñas, R.; Salinas-Martín, M.V.; Muñoz, M. The NK-1 receptor is expressed in human primary gastric and colon adenocarcinomas and is involved in the antitumor action of L-733,060 and the mitogenic action of substance P on human gastrointestinal cancer cell lines. Tumor Biol., 2008, 29, 245-54.
18. Luo, W.; Sharif, T.R.; Sharif, M. Substance P-induced mitogenesis in human astrocytoma cells correlates with activation of the mitogen-activated protein kinase signaling pathway. Cancer Res., 1996, 56, 4983-91.
19. Bigioni, M.; Benzo, A.; Irrisuto, C.; Maggi, CA.; Goso, C. Role of NK-1 and NK-2 tachykinin receptor antagonism on the growth of human breast carcinoma cell line MDA-MB-231. Anticancer Drugs, 2005, 16, 1083-9.
20. Esteban, F.; Muñoz, M.; González-Moles, M.A.; Rosso, M. A role for substance P in cancer promotion and progression: a mechanism to counteract intracellular death signals following oncogene activation or DNA damage. Cancer Metast. Rev., 2006, 25, 137-45.
21. Muñoz, M.; Rosso, M.; González-Ortega, A.; Coveñas, R. The NK-1 receptor antagonist L-732,13 8 induces apoptosis and counteracts substance P-related mitogenesis in human melanoma cell lines. Cancers, 2010, 2, 611-23.
22. Muñoz, M.; Rosso, M.; Coveñas, R. The Nk-1 receptor: a new target in cancer therapy. Curr. Drug Targets., 2011, 12, 909-21.
23. Muñoz, M.; González-Ortega, A.; Coveñas, R. The NK-1 receptor is expressed in human leukemia and is involved in the antitumor action of aprepitant and other NK-1 receptor antagonists on acute lymphoblastic leukemia cell lines. Invest. New Drugs, 2011, DOI 10.1007/s10637-010-9594-0.
24. Reubi, J.C. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr. Rev., 2003, 24, 389-427.
25. Berger, A.; Santic, R.; Hauser-Kronberger, C.; Schilling, F.H.; Kogner, P.; Ratschek, M.; Gamper, A.; Jones, N.; Sperl, W.; Kofler, B. Galanin and galanin receptors in human cancers. Neuropeptides, 2005, 39, 353-9.
26. Singh, D.; Joshi, D.D.; Hameed, M.; Qian, J.; Gascon, P.; Maloof, P.B.; Mosenthal, A.; Rameshwar P. Increased expression of preprotachykinin-I and neurokinin receptors in human breast cancer cells: implications for bone marrow metastasis. Proc. Natl. Acad. Sci. USA., 2000, 97, 388-93.
27. Hennig, I.M.; Laissue.; J.A.; Horisberger, U.; Reubi, J.C. Substance-P receptors in human primary neoplasms: tumoral and vascular localization. Int. J. Cancer, 1995, 61, 786-92.
28. Fowler, C.J.; Brannstrom, G. Substance P enhances forskolinstimulated cyclic AMP production in human UC11MG astrocytoma cells. Methods. Find. Exp. Clin. Pharmacol., 1994, 16, 21-8.
29. Morgan, G.; Ward, R.; Barton, M. The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies. Clin. Oncol. (R. Coll. Radiol.), 2004, 16, 549-60.
30. Palma, C.; Bigioni, M.; Irrissuto, C.; Nardelli, F.; Maggi, C.A.; Manzini, S. Anti-tumour activity of tachykinin NK1 receptor antagonists on human glioma U373 MG xenograft. Br. J. Cancer, 2000, 82, 480-7.
31. Mai, J.K.; Stephens, P.H.; Hopf, A.; Cuello, A.C. Substance P in the human brain. Neuroscience, 1986, 17, 709-39.
32. Furuya, S.; Furuya, K.; Shigemoto, R.; Sokabe, M. Localization of NK-1 receptors and roles of substance P in subepithelial fibroblasts of rat intestinal villi. Cell Tissue Res., 2010, 342, 243-59.
33. Haneda, E.; Higuchi, M.; Maeda, J.; Inaji, M.; Okauchi, T.; Ando, K.; Obayashi, S.; Nagai, Y.; Narazaki, M.; Ikehira, H.; Nakao, R.; Zhang, MR.; Suzuki, K.; Suzuki, H.; Suhara, T. In vivo mapping of substance P receptors in brains of laboratory animals by highresolution imaging system. Synapse, 2007, 61, 205-15.
34. Quartara, L.; Maggi, C.A. The tachykinin NK1 receptor. Part I: ligands and mechanisms of cellular activation. Neuropeptides, 1997, 31, 537-63.
35. Douglas, S.D.; Leeman, S.E. Neurokinin-1 receptor: functional significance in the immune system in reference to selected infections and inflammation. Ann. NY Acad. Sci., 2011, 1217, 83-95.
36. Hökfelt, T.; Pernow, B.; Wahren, J. Substance P: a pioneer amongst neuropeptides. J. Intern. Med., 2001, 249, 27-40.
37. 2+ influx through TRPC3. Neurochem. Int., 2010, 57, 923-34.
38. Quartara, L.; Maggi, C.A. The tachykinin NK1 receptor. Part II: distribution and pathophysiological roles. Neuropeptides, 1998, 32, 1-49.
39. Varty, G.B.; Cohen-Williams, M.E.; Hunter, J.C. The antidepressant-like effects of neurokinin NK1 receptor antagonists in a gerbil tail suspension test. Behav. Pharmacol., 2003, 14, 87-95.
40. Bang, R.; Sass, G.; Kiemer, A.K.; Vollmar, A.M.; Neuhuber, W.L.; Tiegs, G. Neurokinin-1 receptor antagonists CP-96,345 and L-733,060 protect mice from cytokine-mediated liver injury. J. Pharmacol. Exp. Ther., 2003, 305, 31-9.
41. Koon, H.W., Shih, D.; Karagiannides, I.; Zhao, D.; Fazelbhoy, Z.; Hing, T.; Xu, H.; Lu, B.; Gerard, N.; Pothoulakis, C. Substance P modulates colitis-associated fibrosis. Am. J. Pathol., 2010, 177, 2300-9.
42. Castellani, M.L.; Galzio, R.J.; Felaco, P.; Tripodi, D.; Toniato, E.; De Lutiis, M.A.; Conti, F.; Fulcheri, M.; Conti, C.; Theoharides, T.C.; Caraffa, A.; Antinolfi, P.; Felaco, M.; Tete, S.; Pandolfi, F.; Shaik-Dasthagirisaheb, Y.B. VEGF, substance P and stress, new aspects: a revisited study. J. Biol. Regul. Homeost. Agents, 2010, 24, 229-37.
43. Vinet-Oliphant, H.; Alvarez, X.; Buza, E.; Borda, J.T.; Mohan, M.; Aye, P.P.; Tuluc, F.; Douglas, S.D.; Lackner, A.A. Neurokinin-1 receptor (NK1-R) expression in the brains of SIV-infected rhesus macaques: implications for substance P in NK1-R immune cell. Am. L. Pathol., 2010, 177, 1286-97.
44. Frisch, P.; Bilkei-Gorzó, A.; Rácz, I.; Zimmer, A. Modulation of the CRH system by substance P/NKA in an animal model of depression. Behav. Brain Res., 2010, 213, 103-8.
45. Hegde, A.; Koh, Y.H.; Moochhala, S.M.; Bhatia, M. Neurokinin-1 receptor antagonist treatment in polymicrobial sepsis: molecular insights. Int. J. Inflam., 2010, 2010, 601098.
46. Khare, V.K.; Albino, A.P.; Reed, J.A. The neuropeptide/mast cell secretagogue substance P is expressed in cutaneus melanocytic lesions. J. Cutan. Pathol., 1998, 25, 2-10.
47. Tarkkanen, A.; Tervo, T.; Tervo, K.; Eranko, L.; Eranko, O.; Cuello, A.C. Substance P immunoreactivity in normal human retina and in retinoblastoma. Ophthalmic. Res., 1983, 15, 300-6.
48. Ziche, M.; Morbidelli, L.; Pacini, M.; Gepetti, P.; Alessandri, G.; Maggi, C.A. Substance P stimulates neovascularization in vivo and proliferation of cultured endothelial cells. Microvasc. Res., 1990, 40, 264-78.
49. Feng, F.; Yang, J.; Tong, L.; Yuan, S.; Hong, L.; Wang, W.; Zhang, H. Substance P immunoreactive nerve fibers are related to gastric cancer differentiation status and could promote proliferation and migration of gastric cancer cells. Cell Biol. Int., 2011, DOI: 10.1042/CBI20100229.
50. Johnson, C.L.; Johnson, C.G.; Stauderman, K.A.; Buck, S.H. Characterization of substance receptors in human astrocytoma cells. Ann. NY. Acad. Sci., 1991, 632, 410-2.
51. Grady, E.F.; Garland, A.M.; Gamp, P.D.; Lovett, M.; Payan, D.G.; Bunnett, N.W. Delineation of the endocytic pathway of substance P and its seven transmembrane domains NK1 receptor. Mol. Biol. Cell., 1995, 6, 509-24.
52. Mantyh, P.W.; Allen, C.J.; Ghilardi, J.R.; Rogers, S.D.; Mantyh, C.R.; Liu, H.; Basbaum, A.I.; Vigna, S.R.; Maggio, J.E. Rapid endocytosis of a G protein-coupled receptor: substance P evoked internalization of its receptor in the rat striatum in vivo. Proc. Natl. Acad. Sci, USA., 1995, 92, 2622-6.
53. Payan, D.G.; Brewster, D.R.; Goetzl, E.J. Specific stimulation of human T lymphocytes by substance P. J. Immunol., 1983, 131, 1613-5.
54. Ziche, M.; Morbidelli, L.; Pacini, M.; Dolara P.; Maggi, C.A. NK1-receptors mediate the proliferative response of human fibroblasts to tachykinins. Br. J. Pharmacol., 1990, 100, 11-4.
55. Entschladen, F.; Lang, K.; Drell, T.L.; Joseph, J.; Zaenker, K.S. Neurotransmitters are regulators for the migration of tumor cells and leukocytes. Cancer Immunol. Immunother., 2002, 51, 467-82.
56. Meshki, J.; Douglas, S.D.; Lai, J.P.; Schwartz, L.; Kilpatrick, L.E.; Tuluc, F. Neurokinin 1 receptor mediates membrane blebbing in HEK293 cells through a Rho/Rho-associated coiled-coil kinasedependent mechanism. J. Biol. Chem., 2009, 284, 9280-9.
57. Fackler, O.T.; Grosse, R. Cell motility through plasma membrane blebbing. J. Cell. Biol., 2008, 181, 879-84.
58. Huang, S.C.; Korlipara, V.L. Neurokinin-1 receptor antagonists: a comprehensive patent survey. Expert. Opin. Ther. Pat., 2010, 20, 1019-45.
59. Millan, M.J.; Dekeyne, A.; Gobert, A.; Mannoury la Cour, C.; Brocco, M.; Rivet, J.M.; Di Cara, B.; Lejeune, F.; Cremers, T.I.; Flik, G.; de Jong, T.R.; Olivier, B.; de Nanteuil, G. S-41,744, a dual neurokinin (NK) 1 receptor antagonist and serotonin (5-HT) reuptake inhibitor with potential antidepressant properties: a comparison to aprepitant (MK869) and paroxetine. Eur. Neuropsychopharmacol., 2010, 20, 599-621.
60. Rost, K.; Fleischer, F.; Nieber, K. Neurokinin-1 receptor antagonists: between hope and disappointment. Med. Monatsschr. Pharm., 2006, 29, 200-5.
61. Giuliani, G.; Cappelli, A.; Matarrese, M; Masiello, V.; Turolla, E.A.; Monterisi, C.; Fazio, F.; Anzini, M.; Pericot Mohr, G.L.; Riitano, D.; Finetti, F.; Morbidelli, L.; Ziche, M.; Giorgi, G.; Vomero, S. Non-peptide NK(1) receptor ligands based on the 4-phenylpyridine moiety. Bioorg. Med. Chem., 2011, 19, 2242-51.
62. Obach, R.S.; Margolis, J.M.; Logman, M.J. In vitro metabolism of CP-122,721(2S,3S)-2-phenyl-3-[(5-trifluoromethoxy-2-methoxy)benzylamino]piperidine), a non-peptide antagonist of the substance P receptor. Drug Metab. Pharmacokinet., 2007, 22, 336-49.
63. Sindrup, S.H.; Graf, A.; Sfikas, N. The NK1-receptor antagonist TKA731 in painful diabetic neuropathy: a randomized, controlled trial. Eur. J. Pain, 2006, 10, 567-71.64.
64. Kart, E.; Jocham, G.; Müller, C.P.; Schlömer, C.; Brandão, M.L.; Huston, J.P.; de Souza Silva, M.A. Neurokinin-1 receptor antagonism by SR140,333: enhanced in vivo ACh in the hippocampus and promnestic post-trial effects. Peptides, 2004, 25, 1959-69.
65. Muñoz, M.; Coveñas, R. NK-1 receptor antagonists: a new paradigm in pharmacological therapy. Curr. Med. Chem., 2011, 18, 1820-31.
66. Largent-Milnes, T.M.; Yamamoto, T.; Nair, P.; Moulton, J.W.; Hruby, V.J.; Lai, J.; Porreca, F.; Vanderah, T.W. Spinal or systemic TY005, a peptidic opioid agonist/neurokinin 1 antagonist, attenuates pain with reduced tolerance. Br. J. Pharmacol., 2010, 161, 986-1001.
67. Rudick, C.N.; Schaeffer, A.J.; Klumpp, D.J. Pharmacologic attenuation of pelvic pain in a murine model of interstitial cystitis. BMC Urol., 2009, 9, 16.
68. Sahbaie, P.; Shi, X.; Guo, T.Z.; Qiao, Y.; Yeomans, D.C.; Kingery, W.S.; Clark, J.D. Role of substance P signaling in enhanced nociceptive sensitization and local cytokine production after incision. Pain, 2009, 145, 341-9.
69. Rupniak, N.M.; Carlson, E.C.; Harrison, T.; Oates, B.; Seward, E.; Owen, S.; de Felipe, C.; Hunt, S.; Wheeldon, A. Pharmacological blockade or genetic deletion of substance P (NK(1) receptors attenuates neonatal vocalization in guinea-pigs and mice. Neuropharmacology, 2000, 39, 1413-21.
70. Bolay, H.; Reuter, U.; Dunn, A.K.; Huang, Z.; Boas, D.A.; Moskowitz, M.A. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med., 2002, 8, 136-42.
71. Zachrisson, O.; Lindefors, N.; Brené, S. A tachykinin NK1 receptor antagonist, CP-122,721-1, attenuates kainic acid-induced seizure activity. Brain Res. Mol. Brain Res., 1998, 60, 291-5.
72. Yu, J.; Cadet, J.L.; Angulo, J.A. Neurokinin-1 (NK-1) receptor antagonists abrogate methamphetamine-induced striatal dopaminergic neurotoxicity in the murine brain. J. Neurochem., 2002, 83, 613-22.
73. Pagán, B.; Isidro, A.A.; Coppola, D.; Chen, Z.; Ren, Y.; Wu, J.; Appleyard, C.B. Effect of a neurokinin-1 receptor antagonist in a rat model of colitis-associated colon cancer. Anticancer Res., 2010, 30, 3345-53.
74. Wang, Y.; Mu, X.; Liu, Y.; Zhang, X.; Wu, A:, Yue, Y. NK-1-receptor-mediated lesion of spinal post-synaptic dorsal column neurons might improve intractable visceral pain of cancer origin. Med. Hypotheses, 2011, 76, 102-4.
75. Hargreaves, R.; Ferreira, J.C.; Hughes, D.; Brands, J.; Hale, J.; Mattson, B.; Mills S. Development of aprepitant, the first neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Ann. NY Acad. Sci., 2011, 1222, 40-8.
76. Diemunsch, P.; Grelot, L. Potential of substance P antagonists as antiemetics. Drugs, 2000, 60, 533-46.
77. Ständer, S.; Siepmann, D.; Herrgott, I.; Sunderkötter, C:, Luger, T.A. Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy. PLoS One, 2010, 5, e10968.
78. Muñoz, M.; Rosso, M. The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug. Invest. New Drugs, 2010, 28, 187-93.
79. Rosati, R.; Adil, M.R.; Ali, M.A.; Eliason, J.; Orosz, A.; Sebestye, N.F.; Kalemkerian, G.P. Induction of apoptosis by a short-chain neuropeptide analog in small cell lung cancer-stimulation of multiple neuropeptides and inhibition by broad spectrum antagonists in vitro and in vivo. Peptides, 1998, 19, 1519-23.
80. 11] Substance P, a potent bombesin antagonist in murine Swiss 3T3 cells, inhibits the growth of human small cell lung cancer cells in vitro. Proc. Natl. Acad. Sci. USA., 1988, 35, 1859-63.
81. 11] Substance P induces apoptosis in lung cancer cell lines in vitro. Biochem. Bioph. Res. Com., 1994, 199, 1313-9.
82. El-Salhy, M.; Starefeldt, A. Direct effects of octreotide, galanin and serotonin on human colon cancer cells. Oncol. Rep., 2003, 10, 1723-8.
83. Akazawa, T.; Kwatra, S.G.; Goldsmith, L.E.; Richardson, M.D.; Cox, E.A.; Sampson, J.H.; Kwatra, M.M. A constitutively active form of neurokinin 1 receptor and neurokinin 1 receptor-mediated apoptosis in glioblastomas. J. Neurochem., 2009, 109, 1079-86.
84. Huang, W.Q.; Wang, J.G.; Chen, L.; Wei, H.J.; Chen, H. SR140333 counteracts NK-1 mediated cell proliferation in human breast cancer cell line T47D. J. Exp. Clin. Cancer Res., 2010, 24, 29-55.
85. DeFea, K.A.; Vaughn, Z.D.; O'Bryan, E.M.; Nishijima, D.; Dery, O.; Bunnett, N.W. The proliferative and antiapoptotic effects of substance P are facilitated by formation of a beta-arrestindependent scaffolding complex. Proc. Natl. Acad. Sci. USA., 2000, 97, 11086-91.
86. Giardina, G.A.M.; Gagliardi, S.; Martinelli, M. Antagonists at the neurokinin receptors-Recent patent literature. Drugs, 2003, 6, 758-72.
87. Kramer, M.S.; Cutler, N.; Feighner, J.; Shrivastava, R.; Carman, J.; Sramek, J.J.; Reines, S.A.; Liu, G.; Snavely, D.; Wyatt-Knowles, E.; Halle, J.J.; Mills, S. G,.; MacCoss, M.; Swain, C.J.; Harrison, T.; Hill, R.G.; Hefti, F.; Scolnick, E.M.; Cascieri, M.A.; Chicchi, G.G.; Sadowski, S.; Williams, A.R.; Hewson, L.; Smith, D.; Carlsson, E.J.; Hargreaves, R.J.; Rupniak, N.M. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science, 1998, 281, 1640-5.
88. Lang, K.; Drell, T.L.; Lindecke, A.; Niggemann, B.; Kaltschmidt, C.; Zaenker, K.S.; Entschladen, F. Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs. Int. J. Cancer, 2004, 112, 231-8.
89. Guha, S.; Eibl, G.; Kisfalvi, K.; Fan.; R.S.; Burdick, M.; Reber, H.; Hines, O.J.; Strieter, R.; Rozengurt, E. Broad-spectrum G protein-coupled receptor antagonist, [D-Arg1, DTrp5,7,9, Leu11]SP: a dual inhibitor of growth and angiogenesis in pancreatic cancer. Cancer Res., 2005, 65, 2738-45.
90. Exadaktylos, A.K.; Buggy, D.J.; Moriarty, D.C.; Mascha, E.; Sessler, D.I. Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis? Anesthesiology, 2006, 105, 660-4.
91. Kitchens, C.A.; McDonald, P.R.; Pollack, I.F.; Wipf, P.; Lazo, J.S. Synergy between microtubule destabilizing agents and neurokinin 1 receptor antagonists identified by an siRNA synthetic lethal screen. FASEB. J., 2009, 23, 756.13.
92. Alfieri, A.B.; Cubeddu, L.X. Role of NK1 receptors on cisplatininduced nephrotoxicity in the rat. Naunyn. Schmiebergs. Arch. Pharmacol., 2000, 361, 334-8.
93. Alfieri, A.B.; Cubeddu, L.X. Efectos de los antagonistas de los receptores NK1 y de la dexametasona sobre la inflamación neurogénica inducida por ciclofosfamida y por radiación X, en la rata. AVFT., 2004, 23, 61-6.
94. Sendo, T.; Itoh, Y.; Goromaru, T.; Hirakawa, T.; Ishida, M.; Nakano, H.; Oishi, R. Role of substance P in hypersensitivity reactions induced by paclitaxel, an anticancer agent. Peptides, 2004, 25, 1205-8.